ClinicalTrials.Veeva

Menu
T

Therapeutics Clinical Research | San Diego, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Levulan
Aminolevulinic Acid
Adapalene
ALA
122-0551
Glycopyrronium
M518101
CB-03-01
LY3471851
ESK-001

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 87 total trials

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (EMBARQ-CSU1)

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urtic...

Enrolling
Chronic Spontaneous Urticaria
Biological: barzolvolimab
Biological: Matching placebo

The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and...

Enrolling
Alopecia, Androgenetic
Drug: Clascoterone 5% solution
Drug: Vehicle solution

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Enrolling
Plaque Psoriasis
Drug: Placebo
Drug: Apremilast

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoi...

Enrolling
Cutaneous T Cell Lymphoma
Mycosis Fungoides
Drug: Placebo
Drug: Hypericin

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the pre...

Enrolling
Psoriasis
Obesity
Drug: Tirzepatide
Drug: Ixekizumab

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Enrolling
Psoriasis
Severe Psoriasis
Drug: Open-Label ESK-001
Drug: Blinded ESK-001

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have bee...

Active, not recruiting
Psoriasis
Drug: BMS-986165

The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate...

Active, not recruiting
Moderate Plaque Psoriasis
Drug: Placebo
Drug: Guselkumab

To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients w...

Enrolling
Psoriasis
Plaque Psoriasis
Drug: Placebo
Drug: Hypericin

Trial sponsors

D
Galderma logo
T
Allergan logo
D
S
S
AbbVie logo
A
B

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems